However, theres a growing trend thats capturing attention both in clinical practice and popular culture: GLP-1 microdosing
L-cells function as nutrient sensors, detecting the presence of food components in the intestinal lumen and responding by secreting GLP-1 into the bloodstream
GLP-1s target insulin resistance, cravings, and fat storage, while HRT addresses the hormonal root cause of those shifts
Obesityan indication for GLP-1 treatment
Tirzepatide produced greater A1c reductions than semaglutide in the SURPASS-2 head-to-head trial, making it the stronger option for glycemic control
Patients on GLP-1 medications are at risk of eating too little protein, particularly if their reduced appetite leads them toward lower-calorie, lower-protein food choices